Antibiotics and collateral damage (Q35678948)

9 August 2017

1 reference

title

Antibiotics and collateral damage (English)

1 reference

9 August 2017

0 references

Daryl J Hoban

1

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

Suppl 3

1 reference

9 August 2017

S12-20

1 reference

Gastrointestinal flora and its alterations in critical illness

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Antibiotic policies and control of resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Global aspects of antimicrobial-resistant enteric bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

The future control of bacterial resistance to antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Development of the quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

The quinolones: decades of development and use

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Maintaining fluoroquinolone class efficacy: review of influencing factors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

A critical review of the fluoroquinolones: focus on respiratory infections

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Vancomycin-resistant Enterococcus faecium in a Veterans Affairs Medical Center: association with antibiotic usage

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2803%2990025-1

7 January 2021

10.1016/S1098-3597(03)90025-1

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14992416